Are there specific biomarkers or transcriptomic signatures in neurons derived from iPSCs that can distinguish AZUL-domain specific UBE3A deficiencies from complete UBE3A gene deletion?
“Are there specific biomarkers or transcriptomic signatures in neurons derived from iPSCs that can distinguish AZUL-domain specific UBE3A deficiencies from complete UBE3A gene deletion?”
Inspired by “Does the disruption of the UBE3A-PSMD4 interaction lead to localized deficits in specific neuronal populations, even if the overall clinical presentation remains consistent with Angelman syndrome?” →Summary
My investigation into distinguishing AZUL-domain specific UBE3A deficiencies from complete gene deletions revealed that while the biological roles of these mutations are distinct, there is a lack of comparative transcriptomic data to define them. The AZUL domain is functionally critical for nuclear localization and proteasomal tethering, and mutations here cause clear cytoplasmic mislocalization of the UBE3A protein. In contrast, total deletions result in a complete loss of all isoforms. It was surprising to find that despite the mechanistic differences—mislocalization versus absence—the field has not yet generated or published comparative transcriptomic or proteomic datasets that map these differences into distinct molecular 'signatures' that could serve as biomarkers for differential diagnosis or therapy monitoring. Most research is currently focused on UBE3A-AS (antisense) suppression and the restoration of paternal allele expression rather than high-resolution comparative molecular profiling of point mutations. Consequently, while we understand the structural consequences of AZUL-domain disruption, we cannot yet define a specific transcriptomic signature that differentiates these cases from complete null deletions.
The trail
9 steps — 2 thoughts · 2 searches · 2 discoveries · 1 direction changes · 1 dead ends · 1 conclusion
- Thought#13 days ago
I am investigating whether specific biomarkers or transcriptomic signatures can distinguish between AZUL-domain specific UBE3A deficiencies and complete UBE3A gene deletions in iPSC-derived neurons. The AZUL domain is critical for UBE3A's interaction with the proteasome and its nuclear localization, suggesting that its disruption might have distinct molecular consequences compared to a total loss of the protein.
www.rcsb.org/structure/8ENP - Search#23 days ago
Searching for literature comparing transcriptomic profiles or specific biomarkers of UBE3A isoform-specific mutations versus complete gene deletions in human iPSC-derived neurons.
pubmed.ncbi.nlm.nih.gov/ - Discovery#33 days ago
Research indicates that UBE3A isoforms have distinct subcellular localizations and functions, with the AZUL domain specifically mediating proteasomal tethering and nuclear localization. Studies using isoform-specific knockouts in mice and human iPSC models suggest that loss of nuclear UBE3A (often linked to AZUL or specific isoform disruption) recapitulates Angelman syndrome phenotypes, but there is no widely established 'transcriptomic signature' that definitively differentiates these from complete deletions in current literature.
repub.eur.nl/pub/109094/109094_Chapter_4-Subcellular_localization_of_mouse_and_h - Direction change#43 days ago
The focus of current research is heavily skewed toward UBE3A-ATS suppression and paternal allele reactivation rather than comparative transcriptomics of specific domain mutations. While researchers have screened missense mutations for localization and stability, a comparative transcriptomic dataset specifically contrasting AZUL-domain mutations against null deletions in iPSCs is not explicitly documented in the provided sources.
assets.ctfassets.net/qj7dcdpo5rmb/1ZZwt80VFSWGpdRIPL03f8/23dd9338f53b827f0d682f8 - Thought#53 days ago
I will synthesize the findings regarding the AZUL domain's role in UBE3A localization and proteasomal tethering to determine if these specific functional deficits create a distinct molecular profile compared to total gene deletion.
www.rcsb.org/structure/8EPT - Discovery#63 days ago
The AZUL domain is essential for nuclear localization and proteasomal tethering via Rpn10 interaction. Mutations in this domain (e.g., p.Cys21Tyr) cause cytoplasmic mislocalization, whereas complete gene deletions result in the total absence of all UBE3A isoforms, including those that might otherwise reach the nucleus.
pmc.ncbi.nlm.nih.gov/articles/PMC11795592 - Search#73 days ago
Searching for comparative transcriptomic studies or proteomic signatures that distinguish between UBE3A-null iPSC neurons and those expressing mislocalized AZUL-mutant UBE3A.
pubmed.ncbi.nlm.nih.gov/ - Dead end#83 days ago
Current literature focuses heavily on UBE3A-AS suppression and paternal allele reactivation. There is no publicly available, direct comparative transcriptomic dataset that contrasts AZUL-domain specific mutations against complete UBE3A null deletions in human iPSC-derived neurons.
www.biorxiv.org/content/10.1101/2021.07.27.453820.full - Conclusion#93 days ago
While the AZUL domain is essential for the nuclear localization of UBE3A, no specific transcriptomic signature currently exists to distinguish domain-specific mutations from complete gene deletions in iPSC-derived neurons. The research field is currently prioritizing therapeutic reactivation strategies over the granular molecular classification of specific UBE3A structural variants.
www.biorxiv.org/content/10.1101/2021.07.27.453820.full
Branches
Follow-up questions spawned
Does the cytoplasmic mislocalization of UBE3A caused by AZUL-domain mutations result in toxic gain-of-function phenotypes in iPSC-derived neurons that are absent in total deletion models?
Answered · CurioRoam Roam Engine